sympagesic (500,0 mg + 4,0 mg)/ml roztwór do wstrzykiwań
dechra regulatory b.v. - metamizolum natricum monohydricum + hyoscini butylbromidum - roztwór do wstrzykiwań - (500,0 mg + 4,0 mg)/ml - bydło; koń; pies; świnia
orfadin
swedish orphan biovitrum international ab - nitisinon - tyrosinemias - inne przewodu pokarmowego i przemianę materii narzędzia, - hereditary tyrosinemia type 1 (ht 1)orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht 1) in combination with dietary restriction of tyrosine and phenylalanine. alkaptonuria (aku)orfadin is indicated for the treatment of adult patients with alkaptonuria (aku).
ketalar 10 10 mg/ml roztwór do wstrzykiwań
pfizer europe ma eeig - ketamini hydrochloridum - roztwór do wstrzykiwań - 10 mg/ml
ketalar 50 50 mg/ml roztwór do wstrzykiwań
pfizer europe ma eeig - ketamini hydrochloridum - roztwór do wstrzykiwań - 50 mg/ml
scorpion 325 sc
syngenta agro gmbh regional headquarters_x000d_ technologiepark, d-63477 maintal, republika federalna niemiec - azoksystrobina; difenokonazol - azoksystrobina - 200 g, _x000d_ difenokonazol - 125 g - fungicyd
ortiva top 325 sc
syngenta polska sp. z o.o._x000d_ ul. szamocka, 01-748 warszawa - azoksystrobina - 200 g, _x000d_ difenokonazol - 125 g - fungicyd
tarantula 325 sc
agrosimex sp. z o.o._x000d_ 05-620 goliany - azoksystrobina - 200 g, _x000d_ difenokonazol - 125 g - fungicyd
revus 250 sc
syngenta polska sp. z o.o._x000d_ ul. szamocka, 01-748 warszawa - mandipropamid - mandipropamid - 250 g_x000d_ w 1 litrze środka - fungicyd
mandius 250 sc
agrosimex sp. z o.o._x000d_ 05-620 goliany - mandipropamid - 250 g - fungicyd
blincyto
amgen europe b.v. - blinatumomab - prekursor komórkowy limfoblastyczny białaczka-chłoniak - Środki przeciwnowotworowe - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.